SCHEMBL21634089

SCHEMBL21634089

O=C(Cn1ccc(-c2nnc(C(F)(F)F)o2)cc1=O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 14/20 0.70
▸ HDAC1 Q13547 6/20 0.40
▸ GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21634115 0.89 HDAC6 (0.64) HDAC6
SCHEMBL21634130 0.89 HDAC6 (0.61) HDAC6
SCHEMBL21634112 0.86 HDAC6 (0.62) HDAC6HDAC1
SCHEMBL21634094 0.83 HDAC6 (0.62) HDAC6
SCHEMBL21650573 0.83 HDAC6 (0.53) HDAC6
SCHEMBL21634119 0.83 HDAC6 (0.78) HDAC6HDAC1
SCHEMBL23571109 0.83 HDAC6 (0.69) HDAC6
SCHEMBL21634090 0.83 HDAC6 (0.67) HDAC6
SCHEMBL21634292 0.82 HDAC6 (0.71) HDAC6HDAC1
SCHEMBL21634135 0.82 HDAC6 (0.58) HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11958844-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2024-04-16 — — US disclosed
EP-3827004-B1 4-(1,3,4-OXADIAZOLE-2-YL)PYRIDINE-2(1H)-ONE DERIVATIVES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS FOR THE TREATMENT OF E.G. INFECTIONS CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-10-11 — — EP disclosed
US-20210188831-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2021-06-24 — — US disclosed
EP-3827004-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2021-06-02 — — EP disclosed
WO-2020022794-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2020-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958844-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC1 2/4885GRIN2B 1611/4885
US-20210188831-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 HDAC6 1/4885HDAC1 2/4885GRIN2B 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback